MedTrace Logo

Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years

NCT00464217 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2010-01-05

No results posted yet for this study

Summary

To reproduce or to improve the index of complete responses of protocol LMA-91 with a similar protocol, decreasing the dose of Idarubicin to try to reduce the deaths in induction

Conditions

  • Acute Myeloblastic Leukaemia

Interventions

DRUG

ARA-C

DRUG

Idarubicin

DRUG

Leucomax

Sponsors & Collaborators

  • PETHEMA Foundation

    lead OTHER

Principal Investigators

  • Garcia Laraña Jose, Dr · Hospital Universitario Ramon y Cajal

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-10-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00464217 on ClinicalTrials.gov